Literature DB >> 22018491

Rift Valley fever virus inhibits a pro-inflammatory response in experimentally infected human monocyte derived macrophages and a pro-inflammatory cytokine response may be associated with patient survival during natural infection.

Anita K McElroy1, Stuart T Nichol.   

Abstract

Rift Valley fever virus (RVFV) causes significant morbidity and mortality in humans and livestock throughout Africa and the Middle East. The clinical disease ranges from mild febrile illness, to hepatitis, retinitis, encephalitis and fatal hemorrhagic fever. RVFV NSs protein has previously been shown to interfere in vitro with the interferon response, and RVFV lacking the NSs protein is attenuated in several animal models. Monocytes and macrophages are key players in the innate immune response via expression of various cytokines and chemokines. Here we demonstrate that wild-type RVFV infection of human monocyte-derived macrophages leads to a productive infection and inhibition of the innate immune response via decreased expression of IFN-α2, IFN-β and TNF-α. Using a recombinant virus lacking the NSs protein, we show that this effect is mediated by the viral NSs protein. Finally, analysis of RVF patient samples demonstrated an association between a pro-inflammatory cytokine response and patient survival. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22018491      PMCID: PMC6487494          DOI: 10.1016/j.virol.2011.09.023

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  43 in total

1.  Human Biomarkers of Outcome Following Rift Valley Fever Virus Infection.

Authors:  Anita K McElroy; Jessica R Harmon; Timothy Flietstra; Stuart T Nichol; Christina F Spiropoulou
Journal:  J Infect Dis       Date:  2018-10-20       Impact factor: 5.226

2.  Virulence factor NSs of rift valley fever virus recruits the F-box protein FBXO3 to degrade subunit p62 of general transcription factor TFIIH.

Authors:  Markus Kainulainen; Matthias Habjan; Philipp Hubel; Laura Busch; Simone Lau; Jacques Colinge; Giulio Superti-Furga; Andreas Pichlmair; Friedemann Weber
Journal:  J Virol       Date:  2014-01-08       Impact factor: 5.103

3.  Rift Valley fever virus infection induces activation of the NLRP3 inflammasome.

Authors:  Megan E Ermler; Zachary Traylor; Krupen Patel; Stefan A Schattgen; Sivapriya K Vanaja; Katherine A Fitzgerald; Amy G Hise
Journal:  Virology       Date:  2013-12-03       Impact factor: 3.616

4.  Single-dose immunization with virus replicon particles confers rapid robust protection against Rift Valley fever virus challenge.

Authors:  Kimberly A Dodd; Brian H Bird; Maureen G Metcalfe; Stuart T Nichol; César G Albariño
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

5.  Large-scale chromatin immunoprecipitation with promoter sequence microarray analysis of the interaction of the NSs protein of Rift Valley fever virus with regulatory DNA regions of the host genome.

Authors:  Rima Benferhat; Thibaut Josse; Benoit Albaud; David Gentien; Zeyni Mansuroglu; Vasco Marcato; Sylvie Souès; Bernard Le Bonniec; Michèle Bouloy; Eliette Bonnefoy
Journal:  J Virol       Date:  2012-08-15       Impact factor: 5.103

6.  Interplay between the Virus and Host in Rift Valley Fever Pathogenesis.

Authors:  Kaori Terasaki; Shinji Makino
Journal:  J Innate Immun       Date:  2015-02-27       Impact factor: 7.349

7.  Rift Valley fever virus clearance and protection from neurologic disease are dependent on CD4+ T cell and virus-specific antibody responses.

Authors:  Kimberly A Dodd; Anita K McElroy; Megan E B Jones; Stuart T Nichol; Christina F Spiropoulou
Journal:  J Virol       Date:  2013-03-27       Impact factor: 5.103

8.  Post-exposure vaccination with MP-12 lacking NSs protects mice against lethal Rift Valley fever virus challenge.

Authors:  Brian B Gowen; Kevin W Bailey; Dionna Scharton; Zachery Vest; Jonna B Westover; Ramona Skirpstunas; Tetsuro Ikegami
Journal:  Antiviral Res       Date:  2013-03-21       Impact factor: 5.970

9.  Peripheral Blood Biomarkers of Disease Outcome in a Monkey Model of Rift Valley Fever Encephalitis.

Authors:  Elizabeth R Wonderlich; Amy L Caroline; Cynthia M McMillen; Aaron W Walters; Douglas S Reed; Simon M Barratt-Boyes; Amy L Hartman
Journal:  J Virol       Date:  2018-01-17       Impact factor: 5.103

10.  Cytokine response in mouse bone marrow derived macrophages after infection with pathogenic and non-pathogenic Rift Valley fever virus.

Authors:  Kimberly K Roberts; Terence E Hill; Melissa N Davis; Michael R Holbrook; Alexander N Freiberg
Journal:  J Gen Virol       Date:  2015-03-10       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.